Full Press Release Details
Medical Granted Patent Allowance in Japan; Global Jurisdictions
Recognizing Novel One & Done' Technology
Mass., February 4, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent
Office (JPO) that it intends to grant the Company a patent for its One & Done' guidewire technology for use with
endoluminal interventions. Japan is the second jurisdiction to grant a patent for the One & Done' guidewire technology
and further protects the novel technology the Company is currently developing.
are advancing our LIBERTY Robotic system, specifically the One &Done' technology, and we are committed to establish
and secure barriers of entry through protecting our intellectual property and know-how," commented Harel Gadot, CEO, President
and Chairman. "We have received positive physician and industry feedback since unveiling the LIBERTY Robotic system last
year, and we will integrate their shared opinion as we expand our IP platform."
allowed claims cover a double guidewire (movable core guidewire) comprising a first hollow guidewire (outer tube) and a second
guidewire (inner core) deployed within the first guidewire (outer tube), and an adjuster mechanism operable to displace the second
guidewire (inner core) longitudinally relative to the first guidewire between at least three states. Each such state is characterized
with its distal tip curvature and stiffness.
the Company now holds a total of 41 patents issued/allowed and 22 pending patent applications.
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological
platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes
for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical
is available at http://www.microbotmedical.com.
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to
future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans," "anticipates,"
"expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary
closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY and SCS,
the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, uncertainty in the results of
pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic,
need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing
Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed
with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical
disclaims any intent or obligation to update these forward-looking statements, except as required by law.